Prophylactic Radiation Will Not Prevent Pleural Mesothelioma Metastasis

mesothelioma metastasis prevention

A UK study says prophylactic radiation of the chest wall is unlikely to prevent pleural mesothelioma metastasis.   Pleural mesothelioma is an aggressive cancer caused by asbestos. Tumors start on the lining around the lungs and can spread to the lungs and other organs. Pleural mesothelioma is the most common type of asbestos cancer. Doctors sometimes use procedures that pierce the chest wall to help diagnose mesothelioma or to deal with mesothelioma side effects. Sometimes, new mesothelioma tumors can form along the instrument tracts or in the spot where the chest wall was pierced. When tumors spread it is known as mesothelioma metastasis. Some evidence suggests that radiating the chest wall after a procedure might prevent mesothelioma metastasis in that … Continue reading Prophylactic Radiation Will Not Prevent Pleural Mesothelioma Metastasis »

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds

Alimta for mesothelioma is kidney patients

New research in the Netherlands suggests that patients who would not normally be prescribed Alimta for mesothelioma could still benefit from the gold standard mesothelioma treatment. The key is an alternate dosing strategy. Alimta is a powerful drug that works by blocking a molecule needed for cell replication. Right now, doctors do not recommend Alimta for mesothelioma in people with poor kidney function. But Dutch pharmacology experts now say it is possible to adjust the dosing to make Alimta safer for these mesothelioma patients. Alimta for Mesothelioma: Proper Dosing is Key The FDA approved Alimta for mesothelioma in 2004. Alimta (pemetrexed) is still the only drug approved for the treatment of malignant mesothelioma. It has also been approved to treat … Continue reading Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds »

Risk of Dying from Mesothelioma Varies by Type, Study Shows

Risk of dying from mesothelioma

The risk of dying from mesothelioma rises and gradually falls  in the decades after exposure for most, but not all, types of asbestos cancer. New research shows those peaks and valleys can vary based on a number of factors. Public health researchers from across Italy recently published their findings on asbestos workers’ risk of dying from mesothelioma. They suggest that the lifetime risk of dying from peritoneal mesothelioma stays high, even after the risk of death from pleural mesothelioma and lung cancer begins to drop off. Quantifying the Risk of Dying from Mesothelioma Asbestos is the primary cause of all three types of mesothelioma: pleural, peritoneal, and pericardial. Pleural mesothelioma is the most common asbestos-related cancer. Pleural tumors start on … Continue reading Risk of Dying from Mesothelioma Varies by Type, Study Shows »

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Cancer Centers May Not Manage Mesothelioma Symptoms Adequately, Study Finds

manage mesothelioma symptoms

UK researchers say the number of patients receiving palliative care to manage mesothelioma symptoms may be lagging behind the need. Nottingham University conducted a needs assessment of more than 700 patients over two years. Seventy percent of patients with pleural mesothelioma or another thoracic cancer completed a questionnaire shortly after diagnosis. Their results revealed a high unmet need for palliation to manage mesothelioma symptoms and those of other thoracic malignancies. How Does Palliative Care Help Manage Mesothelioma Symptoms? Palliative care is any kind of care that helps patients manage mesothelioma symptoms. These can be physical symptoms like breathing difficulty or fatigue. Or they can be psychological symptoms like fear and worry. Palliative care to manage mesothelioma symptoms can include things … Continue reading Cancer Centers May Not Manage Mesothelioma Symptoms Adequately, Study Finds »

Predicting Thyroid Disease After Immunotherapy for Mesothelioma

thyroid disease after imminotherapy

Researchers in Italy say it is possible to predict which mesothelioma patients are likely to develop thyroid disease after immunotherapy. They are advising their colleagues to use the technique for better management of malignant mesothelioma. Immune checkpoint inhibitors like Keytruda are improving the outlook for people with asbestos cancer. But immunotherapy is not without risk. Certain people are prone to develop thyroid disease after immunotherapy. If doctors know ahead of time which mesothelioma patients are at risk, they can be better prepared to manage problems later.   Immune Checkpoint Inhibitors and Thyroid Disease after Immunotherapy Pleural mesothelioma is extremely difficult to treat. Immune checkpoint inhibitors have given many mesothelioma patients new hope. Recent studies suggest that some of these drugs … Continue reading Predicting Thyroid Disease After Immunotherapy for Mesothelioma »

Research Highlights Connection Between BDNF and Mesothelioma Survival

BDNF and mesothelioma survival

French scientists say there is a clear connection between a biomarker called BDNF and mesothelioma survival. The research may open the door to improved mesothelioma diagnosis, prognosis, and treatment. BDNF stands for brain-derived neurotrophic factor. It is a protein found in the brain and other tissues. In a new published study, researchers at the University of Nantes found that mesothelioma patients had higher BDNF levels than people with other cancers. Mesothelioma patients with the highest BDNF levels had the shortest mesothelioma survival. Linking BDNF and Mesothelioma Survival A biomarker is a substance that can be used to show the presence of disease. BDNF is a soluble mesothelioma biomarker. Soluble biomarkers are in body fluid and can be collected without a … Continue reading Research Highlights Connection Between BDNF and Mesothelioma Survival »

Childhood Environmental Asbestos Exposure and Malignant Mesothelioma

Environmental asbestos exposure in Danish children

Environmental asbestos exposure in childhood can dramatically raise the risk for malignant mesothelioma later in life. That is the finding of new mesothelioma research conducted in Denmark. The study appears in the newest issue of Occupational & Environmental Medicine. It included more than 12,000 people who attended school near an asbestos cement plant during a 30-year period. Researchers discovered that kids educated near the plant were much more likely to receive a mesothelioma diagnosis as adults. Environmental Asbestos Exposure in Danish Children Asbestos was once thought to be an ideal component of building products such as insulation, roof tiles, and cement. It has high tensile strength, is impervious to heat and flame, and is and highly resistant to corrosion. On … Continue reading Childhood Environmental Asbestos Exposure and Malignant Mesothelioma »

Defactinib Fails Again as a Maintenance Therapy for Mesothelioma

patient chemotherapy for mesothelioma

There has been another setback for a drug that showed promise as a maintenance therapy for mesothelioma. Defactinib is a focal adhesion kinase (FAK) inhibitor. FAK is a signaling pathway that allows stem cells to give rise to new cancer cells. The developers of defactinib hoped that FAK inhibition would help keep mesothelioma tumors from growing back after chemotherapy. But a team of international researchers has once again concluded that the drug does not work as a maintenance therapy for mesothelioma. In Search of a Maintenance Therapy for Mesothelioma Malignant pleural mesothelioma is an aggressive cancer that is very hard to treat. Standard chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink tumors, but they usually come back. Doctors … Continue reading Defactinib Fails Again as a Maintenance Therapy for Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!